At Chyrscapital they like companies with large presence in domestic pharma market. They like IPCA Labs because it is a stable growth story and expect a sustainable growth of 18-20 percent growth for the long-term.
first published: Jun 6, 2013 02:10 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.